Latest News

New Client Win: Aagami Selected to Lead Outlicensing for Key Biosimilars in Japan and South Korea

Aagami is proud to announce a New Client Win. We have been officially appointed by a prominent, rapidly growing global pharmaceutical company to ...

Published : 16 Jun 2026

Read More

Aagami Wins New Project from French Biotech Client

Aagami has been awarded a new mandate by its French biotech client to support the out-licensing of NFL-101, the client’s lead Phase 3 asset for smok...

Published : 01 Jun 2026

Read More

Aagami Secures Global Strategic Advisory Mandate from existing Client for Phase 3-Ready Cardiovascular Biologic

Aagami, Inc., a boutique global life science strategic consulting firm, has been awarded an exclusive, unrestricted global advisory assignment by a pr...

Published : 01 Jun 2026

Read More

New Client Win: Aagami Secured by French Pharma Innovator with Needle-Free Drug Auto-Injector

Aagami is pleased to announce a new strategic client win with a pioneering France-headquartered pharmaceutical company. Under this newly signed mandat...

Published : 27 Mar 2026

Read More

Aagami has received contract extension from California client for partnering of their first in class eye drop to reverse cataract non-invasively

Our clients’ affinity for us continues to grow. Aagami has received another contract extension. The client is developing small molecule eye dro...

Published : 22 Mar 2026

Read More

New Assignment: Outlicensing and Distribution rights for Marketed Dental gel addressing Periodontitis, Gingivitis, & Caries

Aagami has received a new assignment from an existing client, to support regional/global partnering initiative for their Marketed Dental gel...

Published : 20 Mar 2026

Read More

New Assignment: Out-Licensing FDA validated Ionic Liquid Novel delivery platform (Transdermal and Oral) for complex modalities and overcoming API challenges regarding solubility, absorption, and metabolic effects

Aagami has received a new assignment from their publicly listed Japanese client, to establish R&D collaborations/Licensing partnerships for their&...

Published : 16 Mar 2026

Read More

Contract extension to provide strategic support related to IP sale of distressed clinical stage NCE

Aagami has received contract extension to provide strategic support related to IP sale of distressed clinical stage NCE. A first-in-class no...

Published : 18 Feb 2026

Read More

Announcement: Aagami has entered into a partnership with a reputable firm to assist organizations in raising capital efficiently through a hybrid method that incorporates Reg CF platforms

To better deliver value and help clients reach their goals by optimising resources, Aagami has joined forces with a respected company that assists bus...

Published : 11 Feb 2026

Read More

New Client Win: US company addressing unmet medical needs in CNS, Cardio, Metabolic, and Inflammatory diseases

After a productive JPM week including Biotech Showcase in San Francisco, Aagami has won its first new client of 2026, within few days. Client is ...

Published : 21 Jan 2026

Read More